Catalent, Inc. (CTLT)

Market Cap	10.07B
Revenue (ttm)	4.83B
Net Income (ttm)	421.00M
Shares Out	179.96M
EPS (ttm)	2.35
PE Ratio	23.29
Forward PE	13.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,806
Open	54.03
Previous Close	54.72
Day's Range	55.35 - 56.69
52-Week Range	40.69 - 115.34
Beta	1.23
Analysts	Buy
Price Target	70.89 (+26.64%)
Earnings Date	Feb 7, 2023

About CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 31, 2014
• Employees: 19,000
• Stock Exchange: NYSE
• Ticker Symbol: CTLT

Financial Performance

In 2022, Catalent's revenue was $4.83 billion, an increase of 20.76% compared to the previous year's $4.00 billion. Earnings were $503.00 million, a decrease of -4.91%.

Analyst Forecast

According to 22 analysts, the average rating for CTLT stock is "Buy." The 12-month stock price forecast is $70.89, which is an increase of 26.64% from the latest price.

Price Target

$70.89

(26.64% upside)

Analyst Consensus: Buy